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Combined FDG-PET/CT for the detection
of unknown primary tumors: systematic review
and meta-analysis
Abstract The aim of this study was to
systematically review and meta-analyze
published data on the diagnostic
performance of combined 18F-fluoro-
2-deoxyglucose positron emission
tomography/computed tomography
(FDG-PET/CT) in the detection of
primary tumors in patients with cancer
of unknown primary (CUP). A system-
atic search for relevant studies was
performed of the PubMed/MEDLINE
and Embase databases. Methodological
quality of the included studies was
assessed. Reported detection rates, sen-
sitivities and specificities were meta-
analyzed. Subgroup analyses were
performed if results of individual
studies were heterogeneous. The 11
included studies, comprising a total
sample size of 433 patients with CUP,
had moderate methodological quality.
Overall primary tumor detection rate,
pooled sensitivity and specificity of
FDG-PET/CTwere 37%, 84% (95% CI
78–88%) and 84% (95% CI 78–89%),
respectively. Sensitivity was heteroge-
neous across studies
(P=0.0001), whereas specificity was
homogeneous across studies
(P = 0.2114). Completeness of diag-
nostic workup before FDG-PET/CT,
location of metastases of unknown
primary, administration of CT contrast
agents, type of FDG-PET/CT images
evaluated and way of FDG-PET/CT
review did not significantly influence
diagnostic performance. In conclusion,
FDG-PET/CT can be a useful method
for unknown primary tumor detection.
Future studies are required to prove the
assumed advantage of FDG-PET/CT
over FDG-PET alone and to further
explore causes of heterogeneity.
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Introduction
Cancer of unknown primary (CUP), defined as the
presence of histologically proven metastatic disease for
which the site of origin cannot be identified at the time of
diagnosis (despite comprehensive diagnostic workup), is
one of the ten most frequent cancers (accounting for 3–5%
of all malignancies) and is the fourth most common cause
of cancer-related death [1, 2]. Failure to detect the primary
tumor impedes optimization of treatment planning, which,
in turn, may negatively influence patient prognosis.
18F-
fluoro-2-deoxyglucose positron emission tomography
(FDG-PET) allows whole-body tumor detection [3] and
has proven to be useful in patients with CUP for the
detection of the primary tumor [4–6]. A disadvantage of
FDG-PET, however, is its lack of anatomic information,
which may impede precise localization of FDG accumula-
tion. Furthermore, tumors with low or even no FDG uptake
may be missed by FDG-PET. Complimentary anatomic
information, provided by computed tomography (CT) or
magnetic resonance (MR) imaging, may improve the
diagnostic performance of FDG-PET alone. The relatively
recently introduced combined FDG-PET/CT scanner
allows obtaining both functional and anatomic images in
T. C. Kwee (*)
Department of Radiology,
University Medical Center Utrecht,
Heidelberglaan 100,
3584 CX Utrecht, The Netherlands
e-mail: thomaskwee@gmail.com
Tel.: +31-88-7556687
Fax: +31-30-2581098
R. M. Kwee
Department of Radiology,
University Medical Center Maastricht,
Maastricht, The Netherlandsa single examination [7, 8] and may be of great value for
the detection of primary tumors in patients with CUP. The
purpose of this study was therefore to systematically
review and meta-analyze published data on the diagnostic
performance of FDG-PET/CT in unknown primary tumor
detection.
Methods
Search strategy
A computer-aided search of the PubMed/MEDLINE
and Embase databases was conducted to find relevant
published articles on the diagnostic performance of
combined FDG-PET/CT in primary tumor detection in
patients with CUP. The search strategy is presented in
Table 1. No beginning date limit was used. The search
was updated until 13 March 2008. Only English-,
German-, French-, Italian- or Spanish-language studies
were considered because the investigators were familiar
with these languages. To expand our search, biblio-
graphies of articles that finally remained after the
selection process were screened for potentially suitable
references.
Study selection
Studies or subsets in studies investigating the diagnostic
performance of FDG-PET/CT in primary tumor detection
in patients with CUP were eligible for inclusion. Review
articles, meta-analyses, abstracts, editorials or letters, case
reports, guidelines for management and studies examining
ten or fewer patients with CUP were excluded. Studies or
subsets in studies were excluded if metastases were not
histologically confirmed. Studies that provided insufficient
data to construct a 2×2 contingency table to calculate
sensitivity and specificity for primary tumor detection in
patients with CUP were also excluded. When data were
presented in more than one article, the article with the
largest number of patients or the article with the most
details was chosen.
Two researchers (T.C.K., R.M.K.) independently re-
viewed the titles and abstracts of the retrieved articles,
applying the inclusion and exclusion criteria mentioned
above. Articles were rejected if they were clearly ineligible.
The same two researchers then independently reviewed the
full-text version of the remaining articles to determine their
eligibility for inclusion. Disagreements were resolved in a
consensus meeting.
Data abstraction
For each included study, information was collected
concerning basic study and patient characteristics (author
names, year of publication, country of origin, study design,
number, age and sex ratio of investigated patients, location
of metastases of unknown primary, histology of metastases
of unknown primary and diagnostic workup before FDG-
PET/CT), FDG-PET/CT parameters (time of fasting before
FDG administration, FDG dose, time interval between
FDG administration and data acquisition, number of CT
detector rows, reconstructed CTslice width, administration
of intravenous and/or oral CT contrast agents and area of
body examined) and FDG-PET/CT evaluation (evaluation
of attenuation-corrected and/or non-attenuation corrected
images, interpreters(s) of FDG-PET/CT, criteria for posi-
tivity and applied reference standard).
To calculate estimates of diagnostic performance (i.e.,
primary tumor detection rate, sensitivity and specificity), a
true-positive result was considered when FDG-PET/CT
suggested the location of the primary tumor and was
subsequently confirmed. A false-positive result was
considered when this location was not confirmed. The
sites suggested by FDG-PET/CT were confirmed by
histopathological analysis of tissue obtained by biopsy or
surgery, considered as the reference standard. However,
imaging procedures or clinical follow-up was accepted if
no histopathological proof could be obtained. A true-
negative result was considered when neither FDG-PET/CT
nor the reference standard could detect the primary tumor.
A false-negative result was considered if the primary tumor
was detected in a particular location that was negative on
FDG-PET/CT [4, 6].
Table 1 Search strategy and results as on 13 March 2008
# Search string PubMed/
MEDLINE
Embase
1 Fluorodeoxyglucose OR 2-fluoro-2-deoxy-D-glucose OR FDG OR positron emission tomography
OR positron-emission tomography OR PET
39,616 46,549
2 Computed tomography OR computerized tomography OR computed tomographic OR CT OR CAT 430,940 317,859
3 Unknown primary OR unidentified primary OR occult primary OR unknown origin OR unidentified origin 32,203 25,105
4 #1 AND #2 AND #3 230 185
732Study quality
For each included study, the methodological quality was
assessed by using the Quality Assessment of Studies of
Diagnostic Accuracy Included in Systematic Reviews
(QUADAS) criteria, which is a 14-item instrument [9,
10]. The item “Is the time period between reference
standard and index test short enough to be reasonably
sure that the target condition did not change between
the two tests?” was removed from the standard
QUADAS list, since follow-up is required to verify
negative FDG-PET/CT findings. The item “Did patients
receive the same reference standard regardless of the
index test result?” was removed from the standard
QUADAS list, since positive FDG-PET/CT findings
can be confirmed by means of histology, but negative
FDG-PET/CT findings require follow-up. The item
“Were the reference standard results interpreted without
knowledge of the results of the index test?” was also
removed from the standard QUADAS list, since
Table 2 Criteria list used to assess the methodological quality of the studies
Quality item Positive score
Was the spectrum of patients representative of the patients who will
receive the test in practice?
Patients with histologically confirmed metastatic cancer, in whom
medical history, physical examination, full blood count, basic
biochemistry battery, urinalysis, stool occult blood testing, immuno-
histochemistry with specific markers as well as imaging technology
with chest X-ray, computed tomography of the chest abdomen and
pelvis or mammography and MR imaging in certain cases failed to
detect the primary tumor, were included
Were selection criteria clearly described? It was clear how patients were selected for inclusion
Is the reference standard likely to correctly classify the target
condition?
Histopathological analysis of tissue obtained by biopsy or surgery, or
imaging procedures or clinical follow-up if no histopathological proof
could be obtained
Did the whole sample, or a random selection of the sample, receive
verification using a reference standard of diagnosis?
All patients, or a random sample of patients who underwent FDG-PET/
CT, also underwent the reference standard
Was the reference standard independent of the index test (i.e., the
index test did not form part of the reference standard)?
FDG-PET/CT did not form part of the reference standard
Was the execution of the index test described in sufficient detail to
permit replication of the test?
All of the following parameters were described:
-Time of fasting before FDG administration, FDG dose, time interval
between FDG administration and scanning
-Application of intravenous and/or oral CT contrast
-Scanned area
-Evaluated images (AC and/or nAC)
-Interpreter(s) of FDG-PET/CT mentioned
Was the execution of the reference standard described in sufficient
detail to permit replication?
Besides histopathological analysis of FDG-PET/CT positive findings,
additional diagnostic procedures (e.g., gastroscopy, CT, MR imaging)
and duration of follow-up were described, if applicable
Were the index test results interpreted without knowledge of the
results of the reference standard?
FDG-PET/CT was interpreted without knowledge of the findings of the
reference standard
Were the same clinical data available when test results were
interpreted as would be available when the test is used in
practice?
Interpreter(s) of FDG-PET/CT was/were aware of the histologic nature
of the metastases of unknown primary
Were uninterpretable/intermediate test results reported? All FDG-PET/CT results, including uninterpretable/ indeterminate/
intermediate were reported
Were withdrawals from the study explained? It is clear what happened to all patients who entered the study
Was comparator review bias avoided? Blinding FDG-PET/CT to the other imaging modality, if more than one
imaging modality was applied
AC: attenuation-corrected images
nAC: non-attenuation-corrected images
CT: computed tomography
FDG-PET:
18F-fluoro-2-deoxyglucose
FDG-PET/CT:
18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography
MR: magnetic resonance
733positive FDG-PET/CT findings can be verified by
means of histopathological analysis of tissue obtained
by biopsy or surgery. One item was added to the
standard QUADAS list: “Was comparator review bias
avoided?” The complete list of quality items is
displayed in Table 2. For each item, the two
researchers (TCK, RMK) independently assessed
whether it was fulfilled (yes or no). If it was unclear
from the information provided in an article as to
whether an item was fulfilled, the item was rated as
“unclear.” Both “no” and “unclear” responses were
interpreted as indicating that the quality criterion was
not met. Disagreements were discussed and resolved by
consensus. The total quality score was expressed as a
percentage of the maximum score of 12.
Statistical analysis
Primary tumor detection rates of individual studies were
calculated and totaled. Locations of primary tumors
detected by FDG-PET/CT, locations of false-positives
FDG-PET/CT findings and locations of false-negative
FDG-PET/CT findings were recorded and summarized.
Sensitivities and specificities of FDG-PET/CT in primary
tumor detection (with corresponding 95% CIs) were
calculated from the original numbers given in the included
studies and meta-analyzed using a random effects model.
Where sensitivity or specificity estimates for an individual
study were zero, a continuity correction of 0.5 was added to
every value for that study in order to make the calculation
of sensitivity and specificity defined.
A chi-squared test was performed to test for heteroge-
neity between studies. Heterogeneity was defined as P<
0.10. Differences in sensitivities and specificities due to
different cut-offs (thresholds) used in different studies to
define a positive (or negative) FDG-PET/CT results were
assessedbycomputingtheSpearmancorrelationcoefficient
between the logit of sensitivity and logit of 1-specificity. A
strong positive correlation would suggest the presence of a
threshold effect. Other potential sources for heterogeneity
were explored by assessing whether certain predefined
covariates significantly influenced (i.e., P<0.05) the
relative diagnostic odds ratio (RDOR) [11]. Although the
findings of such analyses should be regarded mainly as
hypothesis generating, statistical significance may suggest
substantialchangesinthediagnosticperformanceofthetest
under study as the covariate changes. Specifically, analyses
were performed according to completeness of diagnostic
workup before FDG-PET/CT (studies that fulfilled quality
item 1 vs. studies that did not fulfill quality item 1
[Table 2]), location of metastases of unknown primary
(cervical vs. extracervical), administration of CT contrast
agents (both intravenous and oral contrast vs. no intrave-
nous or oral contrast agent, or not reported), type of FDG-
PET/CT images evaluated (both attenuation-corrected and
non-attenuation-corrected images vs. attenuation-corrected
images only, or not reported) and way of FDG-PET/CT
review (reported blinding to reference test vs. no or
unreported blinding to reference test.
Statistical analyses were executed using the Statistical
Package for the Social Sciences version 14.0 software
(SPSS Inc., Chicago, IL) and Meta-DiSc statistical soft-
ware version 1.4 (Unit of Clinical Biostatistics, Ramón y
Cajal Hospital, Madrid, Spain) [11].
Results
Literature search
The computer-aided search revealed 230 articles from
PubMed/MEDLINE and 185 articles from Embase
(Table 1). Reviewing titles and abstracts from PubMed/
MEDLINE revealed 17 articles potentially eligible for
inclusion. Reviewing titles and abstracts from Embase
Table 3 Basic study and patient characteristics (1)
Study and year Country of origin Study design No. of patients Age in years (mean, range) Sex (M/F)
Fencl et al. [12], 2007 Czech Republic Retrospective 82 NR NR
Nassenstein et al. [13], 2007 Germany NR 39 60, 39–89 31/8
Fleming et al. [14], 2007 USA Retrospective 22 NR NR
Bruna et al. [15], 2007 France Retrospective 37 59, 31–85 14/23
Wartski et al. [16], 2007 France Retrospective 38 57, 36–80 31/7
Ambrosini et al. [18], 2006 Italy NR 38 59, 41–77 22/16
Fakhry et al. [20] 2006 France Retrospective 22 48, 43–71 17/5
Pelosi et al. [22], 2006 Italy Retrospective 68 63, 42–79 36/32
Nanni et al. [26], 2005 Italy NR 21 60, 41–87 12/9
Freudenberg et al. [27], 2005 Germany Retrospective 21 64, 46–94 16/5
Gutzeit et al. [29], 2005 Germany Retrospective 45 57, 29–95 26/19
NR: not reported
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Study and year Location of metastases of
unknown primary (N)
Histology of metastases of
unknown primary (N)
Diagnostic workup before FDG-PET/CT
Fencl et al. [12], 2007 -Cervical (20) -Anaplastic carcinoma (35) In all patients detailed medical history,
full physical and laboratory examinations
and diagnostic imaging methods
-Extracervical (61) -Adenocarcinoma (24)
-Squamous-cell carcinoma (5)
-Spinocellular carcinoma (7)
-Mucinous carcinoma (10)
-Small-cell carcinoma (1)
Nassenstein et al. [13], 2007 Cervical (39) -Squamous-cell carcinoma (27) In all patients tumor workup including
physical examination, ultrasound, chest
X-ray as well as complete endoscopic
exploration with multiple blind biopsies of
the nasopharynx, tonsils and tongue base
-Adenocarcinoma (5)
-Undifferentiated carcinoma (2)
-Lymphoepithelioid cancer (1)
-Malignant melanoma (1)
-Neuroendocrine cancer (1)
-Papillary carcinoma (1)
-Undifferentiated carcinoma (1)
Fleming et al. [14], 2007 Cervical and
extracervical (22)
NR NR
Bruna et al. [15], 2007 Cervical and
extracervical (37)
-Adenocarcinoma (17) In all but three patients, CT of the neck
and thorax; the three patients without a
CT of the neck and thorax had at least a
chest X-ray. In all patients CT and/or
ultrasound of the abdomen and pelvis.
In 13/23 females mammography and
ultrasound of the breasts, in five
females an additional MR of the breasts.
In 25 patients, invasive diagnostic tests
(endoscopic or surgical), of which 16
were bronchoscopies, 10 upper airway
endoscopies, 9 colonoscopies and 8
gastroscopies
-Squamous-cell carcinoma (14)
- Undifferentiated carcinoma (6)
Wartski et al. [16], 2007 Cervical (38) -Squamous-cell carcinoma (32) In all patients systematic palpation,
fiber-optic laryngoscopy and
nasopharyngoscopy, CT and/or MR
imaging with sections from the skull
base to the mediastinum and rigid
panendoscopy with randomized
biopsies at the most frequent sites
of primary tumor
-Undifferentiated carcinoma (4)
-Mucoepidermoid carcinoma (2)
Ambrosini et al. [18], 2006 NR -Adenocarcinoma (13) In all patients physical examination
and negative laboratory and imaging
tests; all patients underwent
multislice CT and MR imaging
-Epithelial carcinoma (8)
-Squamous-cell carcinoma (5)
-Mucoid adenocarcinoma (2)
-Poorly differentiated carcinoma (2)
-Undifferentiated
adenocarcinoma (2)
-Flat-cell tumor (1)
-Germ-cell tumor (1)
-Melanoma (1)
-Spindle-cell tumor (1)
-Spinous-cell carcinoma (1)
-Transitional-cell carcinoma (1)
735revealed 17 articles potentially eligible for inclusion, of
which 15 were all already identified by the PubMed/
MEDLINE search. Thus, 19 studies [12–30] remained for
possible inclusion and were retrieved in full text version.
Screening of the references of these 19 articles did not bring
up new articles. After reviewing the full article, two articles
[17,19]wereexcludedbecauseapartofthestudypopulation
underwent FDG-PETalone and was not separately analyzed
frompatientsundergoingFDG-PET/CT,twoarticles[25,30]
wereexcludedbecausesensitivityandspecificityforprimary
tumor detection could not be calculated, one article [28]w a s
excluded because it did not separately analyze patients with
CUP, one article [21] was excluded because fewer than ten
patients with CUP were included, one article [23]w a s
Study and year Location of metastases of
unknown primary (N)
Histology of metastases of
unknown primary (N)
Diagnostic workup before FDG-PET/CT
Fakhry et al. [20] 2006 -Cervical (22) -Squamous-cell carcinoma (22) In all patients CT and nasofibroscopy
Pelosi et al. [22], 2006 -Cervical (18) -Undefined carcinoma (32) In all patients physical examination,
laboratory tests and conventional
diagnostic procedures, i.e., chest
X-ray, abdominal contrast
enhancement CT and, on the basis
of suspected primary disease,
chest contrast enhancement CT,
MR imaging, ultrasonography,
mammography and endoscopic
procedures
-Extracervical (50) -Adenocarcinoma (18)
-Squamous-cell carcinoma (8)
-Poorly differentiated carcinoma (5)
-Melanoma (4)
-Urothelial-cell carcinoma (1)
Nanni et al. [26], 2005 -Cervical (3) -Adenocarcinoma (8) In all patients physical examination
(digital rectal examination with tests
for occult blood in the stool, breast
palpation and pelvic examination
in women, prostate and testicular
examination in men) and traditional
diagnostic procedures according to
international guidelines (complete
blood counts, liver and renal function
tests, urine analysis, chest radiography,
CT and/or MRI of the abdomen and
pelvis plus X-ray mammography in
women and prostate-specific antigen
test in men)
-Extracervical (17) -Squamous-cell carcinoma (7)
-Cervical and
extracervical (1)
-Poorly differentiated carcinoma (1)
-Melanoma (1)
-Transitional-cell carcinoma (1)
-Germ-cell tumor (1)
-Spindle-cell carcinoma (1)
-Flat-cell tumor (1)
Freudenberg et al. [27], 2005 Cervical (21) -Squamous-cell carcinoma (14) In all patients clinical, endoscopic,
sonographic and planar radiological
staging (none of the patients had
received a dedicated head and
neck CT before)
-Adenocarcinoma (4)
-Undifferentiated malignancy (3)
Gutzeit et al. [29], 2005 -Cervical (18) -Adenocarcinoma (25) In all patients a complete medical history,
thorough physical examination and
conventional diagnostic strategies
(including comprehensive laboratory
analysis, projectional and cross-sectional
imaging and endoscopic procedures
where indicated)
-Extracervical (27) -Squamous-cell carcinoma (15)
-Undifferentiated carcinoma (5)
CT: computer tomography
FDG-PET/CT:
18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography
MR: magnetic resonance
NR: not reported
Table 4 (continued)
736excludedbecauseitwasaneditorial,andonearticle[24]wa s
excluded because the same data were used in a later study.
Eventually, 11 studies [12–16, 18, 20, 22, 26, 27, 29],
comprisinga total samplesizeof433patientswithCUP,met
allinclusionandexclusioncriteria,andtheywereincludedin
this systematic review. The characteristics of the included
studies are presented in Tables 3, 4, 5 and 6.
Methodological quality assessment
Twelve methodological quality items were assessed for
each of the 11 included studies (Table 7). The total
methodological quality score, expressed as a fraction of
the maximum score, ranged from 42% to 75% (median,
50%).
Table 5 FDG-PET/CT parameters
Study and
year
Time of fasting
before FDG
administration
(h)
FDG dose
(MBq)
Time interval
between FDG
administration
and data
acquisition (min)
No. of CT
detector
rows
Reconstructed
slice width
(mm)
Intravenous
CT contrast
Oral CT
contrast
Area of body
scanned
Fencl et al.
[12], 2007
≥6 350–450 60–90 2 4.0 Yes and no Yes From the skull
base to below
the groin
Nassenstein
et al. [13],
2007
≥4 350 60 2 -3.0 (head
and neck)
Yes Yes From the head
to the upper
thigh -5.0 (chest
and abdomen)
Fleming et al.
[14], 2007
NR 555 75 16 NR NR NR From the top
of the head
to midthigh
Bruna et al.
[15], 2007
≥6 5.5/kg
(max. 550)
60 NR NR NR NR From the top
of the head to
midthigh
Wartski et al.
[16], 2007
≥64 –5/kg 60 NR 5.0 No No From the skull
to the midthigh
Ambrosini
et al. [18],
2006
6 370 60–90 NR NR NR NR “Whole-body”
Fakhry
et al. [20]
2006
≥6 260–330 60 NR NR NR NR From the skull
base to the
thighs
Pelosi et al.
[22], 2006
≥6 222–370 60 NR NR NR NR From neck to
pelvis or from
skull to feet
Nanni et al.
[26], 2005
≥6 370 60–90 NR NR NR NR “Total body scan”
Freudenberg
et al. [27],
2005
≥10 360 60 2 -3.0 (head
and neck)
-No (head
and neck
-No (head
and neck)
Head, neck,
thorax,
abdomen
and pelvis
-5.0 (from
thorax to
pelvis)
-Yes (thorax
to pelvis)
-Yes (thorax
to pelvis)
Gutzeit et al.
[29], 2005
≥4 350 60 2 5.0 Yes Yes Head, neck,
thorax,
abdomen
and pelvis
CT: computed tomography
FDG:
18F-fluoro-2-deoxyglucose
NR: not reported
737Table 6 FDG-PET/CT evaluation
Study and year Evaluated
images
Interpreter(s) of
FDG-PET/CT
Criteria for positivity Reference standard
Fencl et al.
[12], 2007
AC and nAC Seven physicians experienced
in both PET and CT reading
were randomly involved in
routine evaluation of findings;
in the event of any uncertainty,
a second or even a third
opinion was solicited
FDG hypermetabolism at
the site of pathological
changes on CT or marked focal
hypermetabolism at sites
suggestive of malignancy (liver
parenchyma, bone marrow)
despite absence of signs of
pathology at those sites on CT
A diagnosis of the primary site
of a malignancy was classified
as true positive only when it was
confirmed histologically. If the
finding was not confirmed
histologically, the diagnosis was
classified as false positive. An
evaluation was classified as true
negative if neither FDG-PET/CT
nor histological findings or clinical
follow-up (including subsequent
imaging tests) determined the site of
the primary. When the site of the
primary was not identified, but was
proven histologically, the finding was
classified as false negative
Nassenstein
et al. [13],
2007
NR Two different reading teams,
each consisting of a radiologist
and a nuclear medicine physician
Contrast-enhancing mass on
CT or focally increased FDG
uptake on PET
“Full medical history was available
for all patients”
Fleming
et al. [14],
2007
NR One of three neuroradiologists An SUV level greater than 2.5
was considered consistent with
abnormal, hypermetabolic
activity in primary, regional
and distant disease
Each site of increased PET metabolic
activity was compared with operative
histopathology records
Bruna et al.
[15], 2007
NR NR NR -“Follow-up”
-Histology (n = 7)
-Complimentary examination (n = 3),
among which were CT of the
abdomen and pelvis (n = 2)
Wartski
et al. [16],
2007
AC and nAC Two experienced nuclear
medicine physicians,
independently
Increased FDG focal uptake
indicative of a primary tumor
in the head and neck and/or
chest regions
FDG-PET/CT results were correlated
to the patient’s medical record
concerning pathological results
and treatment. A FDG-PET/CT result
was considered as a true positive
when an FDG focus matched the
primary tumor found during the
second panendoscopy, a false positive
when the increased FDG focal uptake
did not match panendoscopy results
and a false negative when the second
panendoscopy detected malignant
lesions with no corresponding
increased FDG focal uptake
Ambrosini
et al. [18],
2006
NR Three nuclear medicine
physicians in consensus
NR -PET/CT findings were subsequently
confirmed by surgery or biopsy
of the primary tumor
-Gastroscopy and 3-month
follow-up in one patient
Fakhry et al.
[20] 2006
NR Two nuclear medicine
physicians
NR (visual interpretation) Histology and/or clinical follow-up
>6 months in all patients
738Diagnostic performance
The results of the 11 included studies are presented in
Tables 8 and 9, and Figs. 1, 2 and 3. Primary tumor
detection rates ranged from 22 to 73%, with an overall
detection rate of 37% (162/433) (Table 8). The most
commonly detected location of the primary tumor by FDG-
PET/CT was the lung, 33% (Fig. 1). The most common
locations of false-positive FDG-PET/CT findings were the
lung and the oropharynx, both 15% (Fig. 2). The most
common cause of false-negative FDG-PET/CT findings
was breast cancer, 27% (Fig. 3). Sensitivity and specificity
of FDG-PET/CT in primary tumor detection ranged from
55% to 100% and from 73% to 100%, with pooled
estimates of 84% (95% CI 78–88%) and 84% (95% CI 78–
89%), respectively (Table 8). The included studies were
statistically heterogeneous in their estimates of sensitivity
(P=0.0001), but homogeneous in their estimates of
specificity (P=0.2114).
A Spearman correlation coefficient of -0.201 (P=
0.554) between the logit of sensitivity and logit of 1-
specificity did not suggest the presence of a threshold
effect. No significantly increased RDORs were ob-
served in any of the subgroup analyses according to
Study and year Evaluated
images
Interpreter(s) of
FDG-PET/CT
Criteria for positivity Reference standard
Pelosi et al.
[22], 2006
NR Two nuclear medicine
physicians in consensus
NR The FDG pathological findings,
suspected for primaries, were further
investigated with other imaging
examination, biopsy and/or surgery
and clinical follow-up (minimum
follow-up of 3 months after the
FDG-PET/CT study)
Nanni et al.
[26], 2005
NR Three skilled nuclear
medicine physicians; in
case of discrepancy, the
FDG-PET/CT interpretation
was reached by consensus
NR -FDG-PET/CT findings were
subsequently confirmed by surgery
or biopsy of the primary tumor
-Gastroscopy in one patient
Freudenberg
et al. [27],
2005
NR Two experienced nuclear
medicine physicians in
consensus (FDG-PET)
and two radiologists (CT)
-FDG-PET: regions of focally
increased tracer uptake (a
maximum SUV of >2.5 was
considered to represent
malignancy in otherwise
equivocal findings)
Histopathology (n=14) and clinical
follow-up ≥9 months (n=7) with
subsequent panendoscopy with biopsy
of the most probable tumor sites
(n=7), ultrasound (n=7), CT (n=6),
MRI (n=6), diagnostic tonsillectomy
(n=4) and additional biopsies (n=4) -CT: contrast-enhancing
masses or asymmetries
typical of malignancies
Gutzeit et al.
[29], 2005
AC and nAC A nuclear medicine
physician and a radiologist,
both with 2 years of
PET/CT experience
Contrast material-enhanced
mass on CT or focally
increased glucose metabolism
with a SUV exceeding
2.5 on FDG-PET
-All potential sites of the primary
tumor depicted by FDG-PET/CT were
histologically verified
-Axillary lymph node dissection in one
FDG-PET/CT-negative patient
-Endoscopy and biopsy of the
esophagus in one FDG-PET/CT-
negative patient
AC: attenuation-corrected images
nAC: non-attenuation-corrected images
CT: computed tomography
FDG-PET:
18F-fluoro-2-deoxyglucose positron emission tomography
FDG-PET/CT:
18F-fluoro-2-deoxyglucose positron emission tomography/computed tomography
PET: positron emission tomography
PET/CT: positron emission tomography/computed tomography
NR: not reported
SUV: standardized uptake value
Table 6 (continued)
739completeness of diagnostic workup before FDG-PET/
CT, location of metastases of unknown primary,
administration of CT contrast agents, type of FDG-
PET/CT images evaluated and way of FDG-PET/CT
review (Table 9).
Discussion
CUP represents a heterogeneous group of metastatic
tumors for which no primary site can be detected following
a thorough medical history, careful clinical examination
and extensive diagnostic workup [1, 2]. Attempts to
identify the primary tumor in patients with CUP are are
often time consuming, expensive and ultimately unsuc-
cessful [1, 2]. The results of this study indicate that, overall,
FDG-PET/CT is able to detect 37% of primary tumors in
patients with CUP, and sensitivity and specificity are
reasonably high (both 84%). Sensitivity, however, was
heterogeneous across studies. Subgroup analysis could not
clarify the observed heterogeneity. It should be noted,
however, that results from our subgroup analysis may not
be conclusive because of the relatively small number of
included studies. Furthermore, it was not possible to
perform subgroup analysis according to the number of CT
detector rows and CT slice width due to incomplete
reporting of included studies. Future studies are required to
further investigate potential sources of heterogeneity.
The results of this systematic review should be
interpreted carefully, since the methodological quality of
the included studies was moderate. Several methodological
shortcomings were identified, of which spectrum bias, bias
due to the use of an inadequate reference standard and
verification bias may seriously have affected the results.
According to Pavlidis et al. [1, 2], the precise clinical
definition of CUP should refer to patients who present with
histologically confirmed metastatic cancer in whom med-
ical history, physical examination, full blood count, basic
Table 7 Quality assessment of the 11 included studies
Study and year Quality items % of maximum score
1234567891 01 11 2
Fencl et al. [12], 2007 - + + + + + - - - + + + 67
Nassenstein et al. [13], 2007 - - - + - + - - - + + + 42
Fleming et al. [14], 2007 - + - - + - - - - + + + 42
Bruna et al. [15], 2007 - + + + - - - - - + + + 50
Wartski et al. [16], 2007 - - - + + + + + - + + + 67
Ambrosini et al. [18], 2006 - - - - - - + - + + + + 42
Fakhry et al. [20] 2006 - + + + - - - - - + + + 50
Pelosi et al. [22], 2006 + - + + - - - - - + ++5 0
Nanni et al. [26], 2005 + - + - + - + + + + ++7 5
Freudenberg et al. [27], 2005 - - + + + + + - - + ++6 7
Gutzeit et al. [29], 2005 - - - - + + + + - + ++5 8
Table 8 Diagnostic performance of FDG-PET/CT in primary tumor detection
Study and year Primary tumor detection rate (%) Sensitivity (%) Specificity (%)
Value 95% CI Value 95% CI
Fencl et al. [12], 2007 22 55 38–70 75 62–85
Nassenstein et al. [13], 2007 28 100 74–100 85 69–94
Fleming et al. [14], 2007 73 94 73–99 100 61–100
Bruna et al. [15], 2007 38 93 70–99 77 57–90
Wartski et al. [16], 2007 34 93 69–99 73 48–89
Ambrosini et al. [18], 2006 53 100 84–100 95 76–99
Fakhry et al. [20] 2006 32 70 40–89 75 47–91
Pelosi et al. [22], 2006 35 83 66–93 87 73–94
Nanni et al. [26], 2005 57 100 76–100 89 57–98
Freudenberg et al. [27], 2005 57 86 60–96 100 65–100
Gutzeit et al. [29], 2005 33 88 66–97 89 73–96
Pooled estimate 37 84 78–88 84 78–89
740biochemistry battery, urinalysis, stool occult blood testing,
immunohistochemistry with specific markers as well as
imaging technology with chest X-ray, CT of the chest
abdomen and pelvis or mammography and MR imaging in
certain cases have failed to detect the primary tumor.
However, only two studies [22, 26] (18%) included
patients who fulfilled these criteria. In the other nine
studies [12–16, 18, 20, 27, 29], diagnostic performance of
FDG-PET/CT might have been overestimated because of
(possible) incomplete diagnostic workup. Furthermore,
only five studies [12, 15, 20, 22, 27] applied an adequate
reference standard of histology and follow-up in all
patients. Consequently, in the other six studies [13, 14,
16, 18, 26, 29], diagnostic performance of FDG-PET/CT
might have been overestimated. Other methodological
flaws include an inadequate description of selection criteria
in seven studies [13, 16, 18, 22, 26, 27, 29] (64%), the
possibility that FDG-PET/CT formed part of the reference
standard (incorporation bias) in five studies [13, 15, 18, 20,
22] (46%), inadequate description of the execution of
FDG-PET/CT in six studies [14, 15, 18, 20, 22, 26] (55%),
inadequate description of the reference standard in six
studies [12–15, 20, 22] (55%), possible interpretation of
FDG-PET/CT while knowing the results of the reference
standard (test review bias) in eight studies [12–15, 18, 20,
22, 27] (73%) and possible interpretation of FDG-PET/CT
without knowledge of the histological nature of the
metastases of unknown primary in nine studies [12–15,
16, 20, 22, 27, 29] (82%).
Lung, oropharyngeal and pancreatic carcinoma were the
most frequently detected primary tumors by FDG-PET/CT
Fig. 1 Locations of primary tumours detected by FDG-PET/CT Fig. 2 Locations of false-positive FDG-PET/CT findings
Table 9 Results of subgroup analysis
Parameter Value No. of studies Relative diagnostic odds ratio (1 vs. 2)
Value 95% CI P-value
Completeness of diagnostic workup before FDG-PET/CT 1. Complete 2 1.93 0.22–17.28 0.5072
2. Incomplete 9
Location of metastases 1. Cervical 6 0.38 0.02–9.55 0.4765
2. Extracervical 2
Administration of CT contrast agents 1. Intravenous and oral 3 2.42 0.32–18.15 0.3347
2. Not reported 7
Evaluated FDG-PET/CT images 1. AC and nAC 3 0.36 0.06–2.09 0.2187
2. AC only or NR 8
Way of FDG-PET/CT review 1. Reported blinding 3 1.18 0.10–13.54 0.8766
2. No reported blinding 8
AC: attenuation-corrected images
nAC: non-attenuation-corrected images
NR: not reported
741in this meta-analysis (33%, 16% and 5%, respectively).
This is partly in line with previous autopsy studies in
patients with CUP [31–34], which have shown that the
most common locations of the primary tumor are the lung
and the pancreas. The high detection rate of oropharyngeal
carcinoma by FDG-PET/CT in this meta-analysis, howev-
er, is discrepant with the results of autopsy studies [31–34].
This finding can by explained by the fact that 4 of 11
included studies [13, 16, 20, 27] exclusively investigated
patients with cervical metastases of unknown primary,
whose primary tumors are most frequently located in the
oropharynx [5, 35]. Indeed, these four studies [13, 16, 20,
27] comprised 69% of all oropharyngeal carcinomas
detected by FDG-PET/CT in this meta-analysis. The
most commonly reported locations of false-positive FDG-
PET/CT results were the lung and the oropharynx (both
15%). Causes of false-positive results may be FDG uptake
in benign conditions with increased glycolysis (e.g., one
false-positive FDG-PET/CT finding in the lung proved to
be a pulmonary infarction [29]), high physiological FDG
uptake (e.g., muscle FDG uptake) and failure to evaluate
both attenuation-corrected and non-attentuation-corrected
images to minimize the chance of misinterpreting (FDG-
PET/CT) artifacts as pathologic (only three of the included
studies [12, 16, 29] explicitly stated that both attenuation-
corrected and non-attentuation-corrected images were
evaluated) [36–38]. Breast cancer was the most common
cause of false-negative FDG-PET/CT results (27%). This
may be explained by the fact that small (<1 cm) and slow-
growing, low-grade (breast) cancers with low or no FDG
uptake (e.g., tubular carcinoma and noninvasive cancers
such as ductal or lobular carcinoma in situ) may be
overlooked on FDG-PET/CT [39].
FDG-PET alone has been thoroughly investigated for
primary tumor detection in patients with CUP; meta-
analyses on FDG-PET reported primary tumor detection
rates ranging between 24.5% and 43%, sensitivities
ranging between 87% and 91.9%, and specificities ranging
between 71% and 81.9% [4–6]. An advantage of FDG-
PET/CTover FDG-PETalone is more accurate localization
of foci with increased FDG uptake, and this may reduce the
problems of physiological FDG uptake being misinter-
preted as pathological and false localization of disease. In
addition, tumors with low or no FDG uptake, or tumors of a
size below the spatial resolution of FDG-PET, may be
depicted by the CT component of FDG-PET/CT. Recently
introduced combined FDG-PET/CT scanners with a 64-
section multidetector CT component and less than 2.5-mm
collimation may detect small primary cancers in the lungs
or oropharynx earlier [40] and are clearly superior to FDG-
PET/CT alone. Furthermore, the additional anatomic data
obtained using FDG-PET/CT may increase the accuracy of
FDG-PET-directed biopsies. Another advantage of FDG-
PET/CT is the use of the CT images for attenuation
correction of the PETemission data, which reduces whole-
body scanning times from 45 min to 30 min or less. This
approach also provides low-noise attenuation correction
factors, compared with those from standard PET transmis-
sion measurements using an external radiation source, and
eliminates bias from emission contamination of postinjec-
tion transmission scans [7, 8]. On the other hand, a
disadvantage of CT-based attenuation correction may be
misclassification of regions containing high concentrations
of CT contrast medium with high-density bone (CT
contrast agents have high atomic numbers relative to the
atomic number of bone, and as the concentration of a
contrast agent increases, its corresponding CT number will
fall within the CT number range for bone), which results in
overcorrection for photon attenuation, consequently lead-
ing to an overestimation of FDG uptake in the contrast-
enhanced region [41,42].Three of the included studies [13,
27, 29] directly compared FDG-PET/CT and (CT-based
attenuation-corrected) FDG-PET alone. In all three studies
[13, 27, 29], FDG-PET/CT was able to detect a few more
primary tumors than FDG-PET alone, but these differ-
ences were not statistically significant. Therefore, FDG-
PET/CT has not yet been proven to be diagnostically
superior to FDG-PET alone. More studies directly
comparing FDG-PET/CT and FDG-PET alone are re-
quired to prove the assumed advantage of FDG-PET/CT
over FDG-PET alone.
Whole-body MR imaging may be an alternative to FDG-
PET/CT [43]; it does not require the operator to work with
a potentially harmful radiotracer, the safety profile of MR
contrast agents is favorable compared with that of iodinated
contrast with CT [44], and the costs for a whole-body MR
imaging examination (about 575 euros) are approximately
two times less than that of a whole-body FDG-PET/CT
examination (about 1,123 euros) [45]. In 1998, Eustace et
al. [46] showed the potential of whole-body MR imaging in
primary tumor detection in four patients with CUP, using a
short-tau-inversion-recovery sequence. However, to our
knowledge, no other reports on the diagnostic performance
Fig. 3 Locations of false-negative FDG-PET/CT findings
742of whole-body MR imaging in unknown primary tumor
detection have been published since then, while (both
anatomical and functional whole-body) MR technology
has continued to evolve [47, 48].
Identification of the primary tumor in patients with CUP
enables accurate tumor staging, which allows optimizing
treatment planning; this, in turn, may improve patient
prognosis. On the other hand, it should be realized that
FDG-PET/CT is an expensive examination, and false-
positive FDG-PET/CT findings may result in unnecessary
additional invasive diagnostic procedures, which have
associated morbidities and costs [49]. In general, it appears
that patients with CUP have a limited life expectancy, with
a median survival of approximately 6–9 months [1, 2], but
a median survival of 23 months has been reported for
patients with CUP and an identified primary tumor
subsequently treated with specific therapy [50]. Similarly,
one study [51] reported that the 3-year survival rate for
patients with cervical metastases and occult oropharyngeal
primary tumors was 100% after treatment, while the
patients with cervical metastases in which a primary tumor
was not detected showed a survival rate of 58%. Only four
studies included in this systematic review reported the
therapeutic impact of FDG-PET/CT; in these four studies,
FDG-PET/CT modified therapy in 18.2–60% of patients
[15, 16, 20, 22]. Although one study [12] reported that the
survival rate of CUP patients with at least one hypermet-
abolic lesion was significantly lower (P<0.0279) than that
of the remaining CUP patients, none of the included studies
reported FDG-PET/CT-modified patient outcomes. There-
fore, the additional value of FDG-PET/CT to patients with
CUP and its cost-effectiveness should be further investi-
gated; the currently presented data can be used to perform
such an analysis.
In conclusion, although included studies were of
moderate methodological quality and their results were
heterogeneous, the results of this systematic review and
meta-analysis indicate that FDG-PET/CT can be a useful
method for unknown primary tumor detection. Future
studies are required to prove the assumed advantage of
FDG-PET/CT over FDG-PET alone and to further explore
causes of heterogeneity.
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